# A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

> clinical trial · VERIFIED · 2026-08-14

Status: RECRUITING · Sponsor: AbbVie · Condition: Non-Small Cell Lung Cancer

- Company: AbbVie
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06568939

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.